Behavidence, Inc.

Behavidence develops a patented mobile application that delivers scientifically validated daily mental health monitoring through digital phenotyping and machine learning. The platform measures mood, focus, worry, and stress by analyzing passive digital biomarkers derived from smartphone usage patterns without tracking message content, websites visited, or typing activity. The solution is designed for healthcare providers (psychiatrists, physicians), clinical trial sponsors, insurance companies, and individual users seeking objective, measurement-based mental health assessment. The app supports standardized psychiatric questionnaires including PHQ-9, GAD-7, and ASRS for structured clinical evaluation. Regulatory credentials include HIPAA compliance and CE marking. Data security employs AES-256 encryption with full user anonymization. The platform offers SDK integration for embedding into existing healthcare IT systems and remote monitoring capabilities to support early intervention strategies. Clinically validated research demonstrates the app's accuracy in detecting mental health deterioration and predicting adverse outcomes. Primary use cases include ongoing patient monitoring in clinical practice, real-time digital phenotype collection for trial efficacy endpoints, and insurance-based early intervention programs for cost reduction. The solution is available on iOS and Android platforms.